<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04699292</url>
  </required_header>
  <id_info>
    <org_study_id>M20DMY</org_study_id>
    <secondary_id>IRBd20-354</secondary_id>
    <nct_id>NCT04699292</nct_id>
  </id_info>
  <brief_title>International Prospective Registry on Local Treatment Approaches in MLS</brief_title>
  <official_title>International Prospective Registry on Local Treatment Approaches in Myxoid Liposarcomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Radboud UMC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastro Clinic, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vienna General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Antwerp</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitetssykehus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitäts-Frauenklinik Graz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Center, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Margaret Hospital, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MOUNT SINAI HOSPITAL</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sydney</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute for Cancer Research and treatment</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Curie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ANZSA (Australia and New Zealand Sarcoma Association)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively study commonly used local treatment approaches in Myxoid Liposarcoma (MLS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to confirm the promising results of the 36 Gy dose level in the DOREMY trial&#xD;
      (NCT02106312) and to compare outcome with other local treatment approaches.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2021</start_date>
  <completion_date type="Anticipated">January 2031</completion_date>
  <primary_completion_date type="Anticipated">January 2031</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Local recurrence free survival</measure>
    <time_frame>From surgery to the end of at least 5 years of follow-up</time_frame>
    <description>Survival from surgery to local recurrence (event) or last follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound complications</measure>
    <time_frame>From surgery to 6 months of follow-up</time_frame>
    <description>Any wound complication requiring intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>From 3 months after surgery to the end of at least 5 years of follow-up</time_frame>
    <description>Any grade ≥2 late (radiation-induced) toxicity according to CTCAE v5.0 toxicity criteria</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient-Reported Outcome Measures (PROMs)</measure>
    <time_frame>From baseline visit to the end of 5 years of follow-up</time_frame>
    <description>PRO-CTCAE Item Library; relevant questions from the Patient-Reported Outcomes version of the CTCAE (PRO-CTCAE)</description>
  </other_outcome>
  <other_outcome>
    <measure>Health-Related Quality of Life (HRQoL)</measure>
    <time_frame>From baseline visit to the end of 5 years of follow-up</time_frame>
    <description>EORTC QLQ-C30; 30-item HRQoL questionnaire; EORTC Items Library; 3 questions to assess some radiotherapy-specific HRQoL; EQ5D-5L; descriptive system for measurement of health; iMCQ; relevant items from the Medical Consumption Questionnaire (iMCQ) to assess medical consumption; PRODISQ; PROductivity and DISease Questionnaire to assess all relevant aspects of the relationship between health and productivity;</description>
  </other_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Myxoid Liposarcoma</condition>
  <arm_group>
    <arm_group_label>Cohort A</arm_group_label>
    <description>MLS patients managed by surgery only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B</arm_group_label>
    <description>MLS patients receiving preoperative RT to a dose of 36 Gy (equivalent) followed by surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort C</arm_group_label>
    <description>MLS patients receiving preoperative RT to a dose of 50 Gy (equivalent) followed by surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort D</arm_group_label>
    <description>MLS patients receiving surgery followed by postoperative RT to a dose of 50-66 Gy (equivalent)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort E</arm_group_label>
    <description>MLS patients with oligometastatic and/or oligoprogressive disease receiving definitive RT to a dose of 36Gy (equivalent)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Surgery</description>
    <arm_group_label>Cohort A</arm_group_label>
    <arm_group_label>Cohort B</arm_group_label>
    <arm_group_label>Cohort C</arm_group_label>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Preoperative RT 36Gy</intervention_name>
    <description>Preoperative radiotherapy to 36Gy (equivalent)</description>
    <arm_group_label>Cohort B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Preoperative RT 50Gy</intervention_name>
    <description>Preoperative radiotherapy to 50Gy (equivalent)</description>
    <arm_group_label>Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Postoperative RT 50-66Gy</intervention_name>
    <description>Postoperative radiotherapy to 50-66Gy (equivalent)</description>
    <arm_group_label>Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>RT 36Gy</intervention_name>
    <description>Definitive radiotherapy to 36Gy (equivalent)</description>
    <arm_group_label>Cohort E</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with Myxoid Liposarcoma (MLS) that will be treated in one of the&#xD;
        participating Sarcoma Reference Centers according to one of the treatment approaches&#xD;
        defined in the 5 cohorts.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Biopsy proven MLS, including the reciprocal chromosomal translocation&#xD;
             t(12;16)(q13;p11)&#xD;
&#xD;
          -  ECOG PS 0-2&#xD;
&#xD;
          -  Written informed consent to share coded information in this international Registry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiotherapy to the target area&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rick Haas, MD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rick Haas, MD/PhD</last_name>
    <phone>+31 20 512 9111</phone>
    <email>r.haas@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jules Lansu, MD/PhD</last_name>
    <phone>+31 20 512 9111</phone>
    <email>j.lansu@nki.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Netherlands Cancer Institute</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Haas, MD/PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jules Lansu, MD/PhD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 6, 2021</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>August 4, 2021</last_update_submitted>
  <last_update_submitted_qc>August 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liposarcoma</mesh_term>
    <mesh_term>Liposarcoma, Myxoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

